Novartis update following WHO Solidarity trial announcement

On May 25, 2020 the World Health Organization (WHO) announced a temporary pause of the hydroxychloroquine (HCQ) arm within the Solidarity trial. The decision was based, in part, on publication in The Lancet 1 of an analysis of hydroxycholoroquine and chloroquine and their effects on hospitalized COVID-19 patients. Novartis has taken note of this retrospective, observational study of existing multinational hospital registry data and our medical teams are evaluating the findings reported in the publication.

The medical evidence on hydroxychloroquine in COVID-19 …

/by

Novartis at ASCO

We are boldly reimagining cancer and blood disorders.

Novartis ASCO20 Virtual Portal

…
/by

Novartis Kisqali® shows overall survival benefit in HR+/HER2- advanced breast cancer with consistent findings in patients with more aggressive disease

  • New MONALEESA-7 (M7) and MONALEESA-3 (M3) subgroup analysis to be presented during ASCO20 Virtual Scientific Program
     
  • Subgroup analysis shows Kisqali plus endocrine therapy extended life compared to endocrine therapy for patients with liver metastases – showing ~47% and 37% reduction in the risk of death in M7 and M3, respectively1
     
  • Visceral metastases, especially liver or brain metastases, generally signify a poor prognosis and more aggressive disease for patients2,3 …
/by

Novartis announces new late-breaking ofatumumab data at EAN demonstrating robust efficacy and safety in the treatment of relapsing forms of multiple sclerosis (RMS)

  • Rapid and profound depletion of B-cells contributed to a halt in disease activity in RMS patients1
     
  • A post hoc analysis showed 47.0% and 87.8% of patients treated with ofatumumab achieved no evidence of disease activity (NEDA-3) within the first (0–12 months) and second year (12–24 months) of treatment, respectively1
     
  • Regulatory action for ofatumumab in RMS in the US is expected in June 2020
     
  • If approved, ofatumumab has the potential to become a first-choice treatment for RMS …
/by